

<シンポジウム 2>アカデミア発の創薬・治療研究

Aim

Chairs Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine
Graduate School of Medicine, Department of Molecular Neuroscience on Neurodegeneration, Tokyo University

Shu-ichi Ikeda, M.D.

Atsushi Iwata, M.D.

(臨床神経 2010;50:837)

Discovery of molecular pathophysiologic mechanisms of neurological diseases brought us new insights into development of disease-modifying therapies for these diseases. They are no longer “untreatable” diseases, but are now “modifiable” or even might be “curable” diseases. In developing disease-modifying therapies based on elucidated molecular

mechanisms of diseases, researchers in academia are expected to play major roles. In this symposium, we will focus on recent achievements on development of disease-modifying therapies and future directions for translation into clinical practice.